Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 3/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | EIF4E | P06730 | 1/20 | 0.35 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.35 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.35 |
| ▸ | PER2 | O15055 | 1/20 | 0.35 |
| ▸ | CRY1 | Q16526 | 1/20 | 0.35 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | SCD | O00767 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2376497 | 1.00 | FURIN (0.37) | FURINMCHR1EIF4EMKNK1MKNK2 | |
| SCHEMBL2380142 | 1.00 | FURIN (0.37) | FURINMCHR1EIF4EMKNK1MKNK2 | |
| SCHEMBL2376487 | 1.00 | FURIN (0.37) | FURINMCHR1EIF4EMKNK1MKNK2 | |
| SCHEMBL2376489 | 1.00 | FURIN (0.37) | FURINMCHR1EIF4EMKNK1MKNK2 | |
| SCHEMBL25346532 | 0.88 | ALDH1A1 (0.37) | SLC6A2SLC6A4SLC6A3ALDH1A1SCD | |
| SCHEMBL12256800 | 0.88 | ALDH1A1 (0.37) | SLC6A2SLC6A4SLC6A3ALDH1A1SCD | |
| SCHEMBL2369645 | 0.88 | ALDH1A1 (0.37) | SLC6A2SLC6A4SLC6A3ALDH1A1SCD | |
| SCHEMBL2369647 | 0.88 | ALDH1A1 (0.37) | SLC6A2SLC6A4SLC6A3ALDH1A1SCD | |
| SCHEMBL12289771 | 0.85 | ALDH1A1 (0.37) | MCHR1SLC6A2SLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL2379911 | 0.85 | ALDH1A1 (0.37) | MCHR1SLC6A2SLC6A4SLC6A3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136338-B2 | Fused thiazolopyrimidine derivatives as MNKs inhibitors | LIFEARC (GB) | 2021-10-05 | — | — | US | disclosed |
| US-20200247822-A1 | Fused Thiazolopyrimidine Derivatives As MNKS Inhibitors | ASTRAZENECA UK LIMITED (GB) | 2020-08-06 | — | — | US | disclosed |
| US-10669284-B2 | Fused thiazolopyrimidine derivatives as MNKS inhibitors | LIFEARC (GB) | 2020-06-02 | — | — | US | disclosed |
| EP-2539345-B1 | 4-[CYCLOALKYLOXY(HETERO)ARYLAMINO]-THIENO[2,3-D]PYRIMIDINES HAVING MNK1/ MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INT (DE) | 2015-07-22 | — | — | EP | disclosed |
| US-8754079-B2 | Cycloalkyl containing thienopyrimidines for pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-17 | — | — | US | disclosed |
| EP-2539345-A1 | 4 - [CYCLOALKYLOXY (HETERO) ARYLAMINO]THIENO [2, 3 - D]PYRIMIDINES HAVING MNKL/ MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS | Boehringer Ingelheim International GmbH (DE) | 2013-01-02 | — | — | EP | disclosed |
| US-20110217311-A1 | CYCLOALKYL CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-08 | — | — | US | disclosed |
| WO-2011104334-A1 | 4 - [CYCLOALKYLOXY (HETERO) ARYLAMINO] THIENO [2, 3 - D] PYRIMIDINES HAVING MNKL/ MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247822-A1 | Fused Thiazolopyrimidine Derivatives As MNKS Inhibitors | MAPT, TTBK1, TTBK2 | FURIN 2687/4885MCHR1 4779/4885EIF4E 622/4885 |
| US-20110217311-A1 | CYCLOALKYL CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DTYMK, CMPK1, UCK2 | FURIN 4654/4885MCHR1 4721/4885EIF4E 2329/4885 |
| US-11136338-B2 | Fused thiazolopyrimidine derivatives as MNKs inhibitors | MAPT, TTBK1, TTBK2 | FURIN 2687/4885MCHR1 4779/4885EIF4E 622/4885 |
| US-10669284-B2 | Fused thiazolopyrimidine derivatives as MNKS inhibitors | MAPT, TTBK1, TTBK2 | FURIN 2699/4885MCHR1 4779/4885EIF4E 635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.